Applications of single‐cell omics for chimeric antigen receptor T cell therapy

Abstract

Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment modality. The breakthroughs in CAR T cell therapy were, in part, possible with the help of cell analysis methods, such as single‐cell analysis. Bulk analyses have provided invaluable information regarding the complex molecular dynamics of CAR T cells, but their results are an average of thousands of signals in CAR T or tumour cells. Since cancer is a heterogeneous disease where each minute detail of a subclone could change the outcome of the treatment, single‐cell analysis could prove to be a powerful instrument in deciphering the secrets of tumour microenvironment for cancer immunotherapy. With the recent studies in all aspects of adoptive cell therapy making use of single‐cell analysis, a comprehensive review of the recent preclinical and clinical findings in CAR T cell therapy was needed. Here, we categorized and summarized the key points of the studies in which single‐cell analysis provided insights into the genomics, epigenomics, transcriptomics and proteomics as well as their respective multi‐omics of CAR T cell therapy.

Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies

“…Furthermore, they contribute to the clinical prediction of therapeutic efficacy and toxicities, enabling a personalized treatment of CAR-T therapy [78,79]. Despite their significance, there have been relatively few reports reviewing the role of modern single-cell sequencing technologies in deciphering CAR-T-cell therapy [45,[80][81][82][83].…”